Yahoo Finance

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants ...

CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing Phase 1/2 VBP101 ...
Yahoo Finance

New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver ...

CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 ...
Business Wire

PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using ...

BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with ...
PharmiWeb

PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using ...

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that ...
Seeking Alpha

PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using ...

New asset VADC45 with significant potential opportunities across oncology, gene therapy, and autoimmune disorders CAMBRIDGE, Mass., Sept. 05, 2024 -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and ...
Seeking Alpha

New Clinical Data Validates Vor Bio’s Approach of Using Shielded Transplants to Deliver ...

Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefit VCAR33 ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with ...